Mabwell (Shanghai) Bioscience Co., Ltd. (688062)
SSE SSE Primary Summary
688062 Chart
People also search for
Mabwell (Shanghai) Bioscience Co., Ltd. (688062) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mabwell (Shanghai) Bioscience Co., Ltd. ever had a stock split?
Mabwell (Shanghai) Bioscience Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Datao Liu CEO | SSE Exchange | CNE100005RD2 ISIN |
| CN Country | 1,491 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Mabwell (Shanghai) Bioscience Co., Ltd. is a pioneering biopharmaceutical enterprise committed to the discovery, development, production, and commercial distribution of innovative biological products. Operating globally from its headquarters in Shanghai, China, Mabwell focuses its efforts on tackling a range of complex diseases. The company’s therapeutic portfolio addresses critical areas such as auto-immune disorders, oncology, ophthalmology, infectious diseases, and metabolic conditions. Since its inception in 2017, Mabwell has made remarkable strides in biopharmaceutical research and development, positioning itself as a notable player in the industry both in China and internationally.
Products and Services
Mabwell offers a diverse array of products and services aimed at providing effective treatments for several critical health conditions. Key offerings include:
- JUNMAIKANG (Autoimmune): An Adalimumab injection designed for the treatment of auto-immune diseases. Adalimumab is a monoclonal antibody that targets TNF-alpha, a substance in the body that causes inflammation in autoimmune diseases.
- Oncology Pipeline:
- 9MW2821 and 6MW3211 (Phase II): These are in the second phase of clinical trials, exploring their efficacy in treating various types of cancer.
- 9MW2921, 9MW3811, and 7MW3711 (Phase I): Early-stage clinical trials aiming to assess the safety profiles of these candidates for cancer treatment.
- 9MW0321: Another promising oncology candidate, though its phase of development is not specified.
- 8MW0511 (Phase III): A more advanced candidate in phase III clinical trial, underscoring its progressive success in previous trial phases.
- Autoimmune Products:
- 9MW1911 and 9MW3811 (Phase 1): These products are in the initial stage of clinical trials, focusing on the treatment of autoimmune diseases.
- Metabolic Products:
- MAILISHU and 9MW3011: Aimed at addressing metabolic disorders, though their phases of clinical development are not detailed.
- Ophthalmology Candidates:
- 9MW0813 and 9MW0211 (Phase III): These are in advanced clinical trials, indicating significant progress towards treating ophthalmologic conditions.
- Infectious Product Candidate:
- 9MW1411: Positioned as a treatment for infectious diseases, though specific phases of its development are not mentioned.
